Sulaf Assi

Dr. Sulaf Assi


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2013 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
OCOrnella Corazza
Ornella Corazza
SASulaf Assi
Sulaf Assi
PSPierluigi Simonato
Pierluigi Simonato
John Martin CorkeryJohn Martin Corkery
John Martin Corkery
FBFrancesco Saverio Bersani
Francesco Saverio Bersani
FSFabrizio Schifano
Fabrizio Schifano

20 February 2013 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
OCOrnella Corazza
Ornella Corazza
SASulaf Assi
Sulaf Assi
FSFabrizio Schifano
Fabrizio Schifano

5 March 2012 in Human Psychopharmacology: Clinical and Experimental
Verified
Journal Article
Closed access
PDF file
OCOrnella Corazza
Ornella Corazza
FSFabrizio Schifano
Fabrizio Schifano
PSPierluigi Simonato
Pierluigi Simonato
Suzanne FergusSuzanne Fergus
Suzanne Fergus
SASulaf Assi
Sulaf Assi
NSNorbert Scherbaum
Norbert Scherbaum

1 July 2014 in International Journal of Drug Policy
Verified
Journal Article
Closed access
OCOrnella Corazza
Ornella Corazza
SASulaf Assi
Sulaf Assi
SMSaeideh Malekianragheb
Saeideh Malekianragheb
MBMitra Naderi Beni
Mitra Naderi Beni
IBImanollah Bigdeli
Imanollah Bigdeli
Fabrizio SchifanoFabrizio Schifano
Fabrizio Schifano

5 February 2013 in Analytical Chemistry
Verified
Journal Article
Closed access
JBJamie Barras
Jamie Barras
DMDarragh Murnane
Darragh Murnane
KAKaspar Althoefer
Kaspar Althoefer
SASulaf Assi
Sulaf Assi
MRMichael D. Rowe
Michael D. Rowe
JSJohn A. S. Smith
John A. S. Smith

1 January 2010 in Journal of Near Infrared Spectroscopy
Verified
Journal Article
Closed access
PDF file
AMAnthony C. Moffat
Anthony C. Moffat
SASulaf Assi
Sulaf Assi
RWRobert A. Watt
Robert A. Watt
Counterfeit medicines are a growing threat to public health across the world and screening methods are needed to allow their rapid identification. A counterfeiter must duplicate both the physical characteristics and the chemical content of a proprietary product to avoid it being detected as a counterfeit product and this is almost impossible to get right. Counterfeit proprietary medicines are, therefore, relatively easy to identify by near infrared (NIR) spectroscopy which can detect physical as well as chemical differences between products by simple spectral comparison. Identifying generic products is more difficult as they use different excipients in the tablet or capsule matrix. Nevertheless, using appropriate models and a large library, NIR spectroscopy can detect counterfeit generic versions. Detecting sub-standard proprietary medicines can be carried out with NIR spectroscopy models and the most widely used is partial least squares regression (PLSR). General rules for generating accurate quantitative models are easy to describe. Quantifying the active pharmaceutical ingredient (API) in generic products can also be carried out using PLSR models with calibration samples generated by manufacturing laboratory samples or by collecting many generic versions of a medicine so as to obtain a good range of the API content in tablets and capsules. Using hand-held instruments or mobile laboratories allows NIR spectrometers to be taken to places where analyses may be made quickly, rather than taking the samples to a laboratory. This has the enormous advantage that the screening of large numbers of samples may be made in pharmacies and wholesalers. Imaging can bring a whole new dimension to NIR spectroscopy to allow the identification of the API and individual excipients as well as measuring the particle sizes of components and giving a measure of the homogeneity of the matrix. The effect of water on potential misidentifications may be obviated by only using blister-packed samples, having large spectral libraries subjected to different humidities or omitting the spectral region where water absorbs.